Arabic Arabic English English French French German German
dark

FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab

FDAToday, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Tokio Marine to acquire US employee benefits firm Standard Security

Next Post

Pfizer to send more COVID vaccines to Canada as Moderna jabs delayed

Related Posts
Total
0
Share